Expert consensus on carotid stenting
This article was originally published in The Gray Sheet
Executive Summary
Stenting the carotid arteries is "a reasonable alternative" to gold-standard carotid endarterectomy in patients at high risk for surgery, according to a clinical expert consensus document published in the Jan. 2/9 Journal of the American College of Cardiology. However, there is insufficient evidence to support carotid stenting in high-risk patients with "asymptomatic stenosis less than 80% or in any patient without high-risk features." CMS likely will consider the consensus when it proposes a revised coverage decision for carotid stenting Feb. 2. Abbott/Guidant requested expanded coverage for all high-risk patients with symptomatic stenosis greater than 50% or asymptomatic stenosis greater than 80% (1"The Gray Sheet" Sept. 11, 2006, p. 6). Currently, Medicare covers symptomatic, high-risk patients with greater than 70% stenosis. Those patients with symptomatic stenosis between 50% and 70% or asymptomatic stenosis greater than 80% are covered only in FDA-approved studies. The consensus document was produced by five professional societies...
You may also be interested in...
Carotid Stent Firms See Another Step Into Market With Expanded Coverage
Carotid artery stent manufacturers hope to maintain momentum in an evolving market in which they see significant potential for growth
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.